FindTrial
Sign In

Observation on the curative effect of Shenling Baizhu sanon sarcopenia

To investigate the molecular mechanism of sarcopenia based on AMPK/SIRT1 signaling pathway

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004493
Enrollment
Unknown
Registered
2021-02-27
Start date
2018-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Experimental group:Shenling Baizhu sanon sarcopenia
Control group:Routine

Sponsors

The Third people's Hospital of Hangzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Conscious subjects; 2. Subjects with certain understanding and activity ability; 3. Subjects aged 65-90 years.

Exclusion criteria

Exclusion criteria: 1. Patients with severe hepatic and renal insufficiency; 2. Subjects with dementia; 3. Subjects unable to participate in the investigation due to acute stroke, severe infection, acute myocardial infarction, severe heart failure and other diseases; 4. Subjects unwilling to cooperate with the investigation; 5. All patients did not take drugs that may affect the bone or metabolism.

Design outcomes

Primary

MeasureTime frame
silent mating type information regulation 2 homolog-1, SIRT1;insulin-like growth factor-1, IGF-1;AMP-activated protein kinase, AMPK-alpha mRNA;growth differentiation factor-8, GDF-8;—

Countries

China

Contacts

Public ContactWang Qin

The Third people's Hospital of Hangzhou

ajin2501@126.com+86 13968006906

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026